ArticleClinical pharmacology and therapeutics2018
Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography.
Open access · hybridAbstract read
In one paragraph
Article in Clinical pharmacology and therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 56 citations in OpenAlex.
- Positron Emission Tomography Imaging of [Clinical pharmacology and therapeutics · 2019Trial
- Resveratrol alters erlotinib pharmacokinetics in rats: application of a rapid HPLC-fluorescence method for quantifying erlotinib in plasma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Imaging the impact of sex and age on OATP function in humans: Consequences for whole-body pharmacokinetics and liver exposure.Acta pharmaceutica Sinica. B · 2025Article
- Organic anion transporting polypeptides: Pharmacology, toxicology, structure, and transport mechanisms.Pharmacological reviews · 2025Review
- Development of quantitative PET/MR imaging for measurements of hepatic portal vein input function: a phantom study.EJNMMI physics · 2024Article
- Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.Molecular pharmaceutics · 2023Article
- Uptake Transporters at the Blood-Brain Barrier and Their Role in Brain Drug Disposition.Pharmaceutics · 2023Review
- The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy.Pharmaceutics · 2023Review
- Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.Acta pharmaceutica Sinica. B · 2023Review
- Advancing Estimation of Hepatobiliary Clearances in Physiologically Based Pharmacokinetic Models of Rosuvastatin Using Human Hepatic Concentrations.Pharmaceutical research · 2021Article
- Impact of Selected Small-Molecule Kinase Inhibitors on Lipid Membranes.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Imaging-Based Characterization of aPharmaceutics · 2021Article
- Review
- Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions.Drug metabolism and disposition: the biological fate of chemicals · 2020Article
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration.International journal of molecular sciences · 2020Review
- Use of imaging to assess the activity of hepatic transporters.Expert opinion on drug metabolism & toxicology · 2020Review
- Article
- Uremic serum residue decreases SN-38 sensitivity through suppression of organic anion transporter polypeptide 2B1 in LS-180 colon cancer cells.Scientific reports · 2019Article
- Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology.Molecular pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 2 countries.
Martin BauerDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Akihiro MatsudaDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Beatrix WulkersdorferDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Cécile PhilippeDepartment of Biomedical Imaging und Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Alexander TraxlCenter for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
Csilla Özvegy-LaczkaInstitute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
Johann StanekDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Lukas NicsDepartment of Biomedical Imaging und Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Eva-Maria KlebermassDepartment of Biomedical Imaging und Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Stefan PoschnerDepartment of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria.
Walter JägerDepartment of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria.
Izabel PatikInstitute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
Éva BakosInstitute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
Gergely SzakácsInstitute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
Wolfgang WadsakDepartment of Biomedical Imaging und Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Marcus HackerDepartment of Biomedical Imaging und Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Markus ZeitlingerDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Oliver LangerDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Medical University of Vienna · ATAustrian Institute of Technology · ATHUN-REN Research Centre for Natural Sciences · HUUniversity of Vienna · ATCenter For Biomarker Research In Medicine · ATInstitute of Molecular Life Sciences · HU
Funding
Austrian Science Fund FWF KLI 480
Abstract
To assess the hepatic disposition of erlotinib, we performed positron emission tomography (PET) scans with [
Indexed as
AdultCarbon RadioisotopesDiffusionErlotinib HydrochlorideFemaleHepatocytesHumansIn Vitro TechniquesLiverLiver-Specific Organic Anion Transporter 1MaleOrganic Anion TransportersPositron-Emission TomographyProtein Kinase InhibitorsSolute Carrier Organic Anion Transporter Family Member 1B3Young AdultCarbon RadioisotopesErlotinib HydrochlorideLiver-Specific Organic Anion Transporter 1Organic Anion TransportersProtein Kinase InhibitorsSLCO1B1 protein, humanSLCO1B3 protein, humanSLCO2B1 protein, humanSolute Carrier Organic Anion Transporter Family Member 1B3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.